Interferon γ-1b
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich's Ataxia
Conditions
Friedreich's Ataxia
Trial Timeline
Dec 25, 2015 → Mar 21, 2017
NCT ID
NCT02593773About Interferon γ-1b
Interferon γ-1b is a phase 3 stage product being developed by Amgen for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT02593773. Target conditions include Friedreich's Ataxia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02797080 | Phase 3 | Completed |
| NCT02593773 | Phase 3 | Completed |
Competing Products
11 competing products in Friedreich's Ataxia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| interferon γ-1b | Amgen | Phase 3 | 76 |
| Interferon γ-1b + Placebo | Amgen | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2/3 | 64 |
| Lu AA24493 + Placebo | Lundbeck | Phase 2 | 49 |
| Omeveloxolone | Biogen | Pre-clinical | 20 |
| Placebo + EPI-743 400 mg + EPI-743 200 mg | PTC Therapeutics | Phase 2 | 49 |
| SGT-212 | Solid Biosciences | Phase 1 | 25 |
| idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone | Santhera Pharmaceuticals | Phase 3 | 69 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |